Metabolic issues associated with protease inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue SUPPL. 1, 2007, Pages

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

AIDS; Diabetes; HIV; Lipids; Metabolic syndrome; Protease inhibitor

Indexed keywords

ATAZANAVIR; EMTRICITABINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC DISORDER; POPULATION; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW;

BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN RESISTANCE; MALE;

EID: 34249689659     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31806007ed     Document Type: Review

References (36)

1. American Stroke Association and American Heart Association. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231-1248.
3. Grundy SM, Pasternak R, Greenland P, et al. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34:1348-1359.
4. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290:932-940.
5. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292-298.
6. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
7. Friis-Moller N, Reiss P, El-Sadr WM, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
8. Reisler RB, Han C, Burman WJ, et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003;34:379-386.
9. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
10. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med. 2006;7:218-230.
11. Wand H, Calmy A, Carey D, et al. Metabolic syndrome, cardiovascular disease, and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults. Presented at: Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2006; San Francisco.
12. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
13. Fitch K, Anderdson E, Hubbard J, et al. Effects of a lifestyle modification program in HIV-infected patients with metabolic syndrome. Presented at: Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2006; San Francisco.
14. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
15. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH publication no. 01-3670. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services; 2001.
16. Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-1508.
17. Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy. 2003;23:1463-1474.
18. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-1504.
19. Hollowell S, Kaye KS, Townsend ML. Achievement of NCEP goals is less frequent among HIV-infected versus non-HIV-infected veterans with dyslipidemia. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005; Washington, DC.
20. Negredo E, Rey-Joly C, Puig J. Ezetimibe, a selective inhibitor of cholesterol absorption, as a new strategy for treatment of hypercholesterolemia secondary to antiretroviral therapy. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005; Washington, DC.
21. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
22. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
23. Malan N, Krantz E, David N, et al. Efficacy and safety of antiretroviral-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
24. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
25. Smith K, Weinberg WG, DeJesus E, et al. Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naive HIV-1 infected patients: 24-week results from COL103952 (ALERT). Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco.
26. Slim J, Avihingsanon A, Ruxrungtham K, et al. Saquinavir/r (SQV/r) bid vs lopinavir (LPV/r) bid plus emtricitabine/tenofovir (FTC/TDF) qd in ARV-naive HIV-1 infected patients: GEMINI study. Presented at: Eighth International Congress on Drug Therapy in HIV Infection; 2006; Glasgow.
27. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735-743.
28. Jackson A, Patel N, Lo G, et al. Effects of atazanavir or saquinavir once daily with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
29. Noor MA, Flint OP, Parker RA, et al. Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir or lopinavir: a prospective, randomized study using hyperinsulinaemic, euglycaemic clamp and oral glucose tolerance testing. Antivir Ther. 2005;10:L11.
30. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
31. Lazzarin A, Quieroz-Telles F, Rockstroh J, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. Presented at: XVI International AIDS Conference; 2006; Toronto.
32. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-20254.
33. Noor MA, Flint OP, Maa JF, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813-1821.
34. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137-2144.
35. Busti AJ, Bedimo R, Margolis D, et al. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir/ritonavir (ATV/RTV): a prospective study using hyperinsulinemic, euglycemic clamp testing. Antivir Ther. 2006;11:L37.
36. Gatell JM. Efficacy and safety of atazanavir (ATV) based HAART in patients switched from a stable boosted/unboosted protease-inhibitor (PI) treatment. Presented at: European AIDS Clinical Society 10th European AIDS Conference; 2005; Dublin.